Great feedback today from various people on how RAP can approach the OSA side of the business. Thank you.
RAP now has a competitive edge that it can offer companies such as RMD, Phillips Respironics, and Fisher & Paykel. This perhaps could lead to licensing deals prior to regulatory approval, with terms and conditions pre-agreed and commenced upon regulatory approval. As@Red bar mentioned this should swiftly achieve regulatory approval in Europe as the data set is huge, results are significant, and way outperformed comparative products. One of these companies may want to lock this technology up, this puts RAP in a great position for bargaining power. RAP may want to keep if for themselves and go direct to market.
It was good to see management truncated the outliers in the data whereby the patients essentially didn't follow protocol and had their partner or animal in the room. Improvements in execution, tick.
Going to be interesting to watch this play out. Looking forward to how the company approaches this part of the business....
That's 3 solid announcements in a small succession of time, the company is building great foundations now. Bring on commercial deals.
RAP Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
